Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets

Dow Jones12-17 22:05

By Adriano Marchese

Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints.

The stock traded 73% lower ahead of the morning bell at $1.18.

The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study.

The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements.

The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life.

Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration.

"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study," said Singh.

The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

December 17, 2025 09:05 ET (14:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592261913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592261913","market":"hk","top_or_hot":-1,"title":"Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Vistagen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints. \n</p>\n<p>\n  The stock traded 73% lower ahead of the morning bell at $1.18. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study. \n</p>\n<p>\n  The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements. \n</p>\n<p>\n  The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life. \n</p>\n<p>\n  Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration. \n</p>\n<p>\n  \"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study,\" said Singh. \n</p>\n<p>\n  The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 09:05 ET (14:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-17 22:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Vistagen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints. \n</p>\n<p>\n  The stock traded 73% lower ahead of the morning bell at $1.18. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study. \n</p>\n<p>\n  The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements. \n</p>\n<p>\n  The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life. \n</p>\n<p>\n  Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration. \n</p>\n<p>\n  \"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study,\" said Singh. \n</p>\n<p>\n  The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 09:05 ET (14:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592261913","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592261913","pubTimestamp":1765980300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints.The stock traded 73% lower ahead of the morning bell at $1.18.The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study.The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements.The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life.Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration.\"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsisten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","VTGN":"VistaGen Therapeutics, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"由于焦虑药物测试未达到目标，Vistagen Therapeutics股价盘前暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"VTGN":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints. \n\n\n  The stock traded 73% lower ahead of the morning bell at $1.18. \n\n\n  The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study. \n\n\n  The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements. \n\n\n  The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life. \n\n\n  Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration. \n\n\n  \"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study,\" said Singh. \n\n\n  The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 09:05 ET (14:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592261913","isCrawlerRequest":true}